Why Is H.B. Fuller Company (FUL) Stock Down -6.38% Today?
Key Takeaways
- FUL shares declined approximately 6.38% in premarket trading on June 25, 2026, falling to around $60.45 from the prior session's close of $62.75
- The primary catalyst was H.B. Fuller's formal confirmation of a £715 million (~$942M) all-cash acquisition of Advanced Medical Solutions Group (AMS), a UK-based medical wound-care company
- A secondary driver was the company's fiscal Q2 earnings report, which — despite beating revenue estimates — delivered a guidance midpoint slightly below analyst consensus, disappointing investors who had priced in a more aggressive outlook
- Activist investor Ancora Holdings, which owns over 2% of FUL shares, had publicly opposed the AMS deal since May, warning of dangerous leverage escalation above 4.0x Net Debt/EBITDA and raising concerns about management's ability to execute a complex cross-border acquisition
- The selloff unfolded against a cautious broader market backdrop, with the S&P 500 and Nasdaq both edging lower
- Traders are watching whether Ancora escalates its opposition to a proxy fight and how credit rating agencies respond to the jump in leverage
Opening Summary
H.B. Fuller Company (FUL), traded on the NYSE, is one of the world's largest standalone specialty adhesives manufacturers, providing bonding, sealing, and coating solutions across construction, electronics, packaging, and industrial markets. Shares dropped approximately 6.38% in Thursday premarket trading, falling from a prior close of $62.75 to roughly $60.45, after the company simultaneously released a mixed quarterly earnings report and formally announced a contested $942 million acquisition. The twin announcements — neither of which fully satisfied market expectations — combined to erase gains built up over the prior several weeks.
The AMS Acquisition: A Deal Market Didn't Want
The dominant driver behind FUL's premarket selloff was the formal announcement of an all-cash offer to acquire Advanced Medical Solutions Group plc (AMS), a UK-listed wound-care and medical adhesives company, at £2.85 per share — representing a 35% premium over AMS's pre-offer closing price and a total enterprise valuation of £715 million (~$942 million including debt). H.B. Fuller argued the deal would grow its total addressable market from $80 billion to $95 billion and generate approximately $55 million in combined revenue and cost synergies by 2031. The AMS board unanimously recommended the offer to its shareholders, and the transaction is expected to close by year-end 2026.
However, investors reacted negatively to the capital allocation decision. Analysts flagged that the fully debt-funded deal is projected to push FUL's leverage above 4.0x Net Debt/Proforma Adjusted EBITDA — a threshold the company's own management had previously pledged to stay below. The AMS transaction moves FUL into unfamiliar medical-device territory with complex European regulatory frameworks, raising integration execution risk.
Activist Opposition Amplifies Selling Pressure
The acquisition announcement confirmed the fears that activist investor Ancora Holdings had been publicly voicing since May 2026. Ancora, with a greater than 2% stake in FUL, had sent sharply worded letters to the board calling the pursuit of AMS "an extremely risky, quasi-transformational international acquisition completely out of management's depth," and warned it would pursue a proxy fight if the deal proceeded. Ancora's concern was that the deal contradicted H.B. Fuller's prior commitments to prioritize debt reduction and share buybacks, noting that the company had repurchased 750,000 shares in Q2 alone while simultaneously moving forward on a leverage-heavy strategic acquisition. With the deal now formally confirmed, the activist's objections transformed from speculative risk into a live corporate governance overhang.
Q2 Earnings: A Beat That Wasn't Enough
On the evening of June 24, FUL reported fiscal Q2 results for the quarter ended May 30, 2026, that technically beat estimates on both lines. Revenue reached $950.3 million, up 5.8% year-over-year and ahead of the $923.67 million consensus, while adjusted EPS came in at $1.41, above the $1.38 estimate. Adjusted EBITDA rose 9% year-over-year to $181 million, and the company generated a record Q2 operating cash flow of $121 million. Despite the beat, the full-year adjusted EPS guidance range of $4.60–$4.90 — with a midpoint of $4.75 — landed just below the analyst consensus of $4.77, signaling to investors that management was not raising the bar aggressively enough given the recent stock run-up of more than 9% over the prior month.
Market Context and Trading Activity
The premarket decline in FUL shares stood out against a broadly flat-to-slightly-lower equity market, with the S&P 500 edging down approximately 0.1% and the Nasdaq declining roughly 0.4% — confirming the move was stock-specific rather than macro-driven. Volume in the premarket session was notably elevated relative to typical pre-open activity, consistent with a dual catalyst event involving both an earnings release and a material M&A announcement. The stock had been trading up over 7% year-to-date ahead of Thursday's session, with a particularly strong run in the prior 30 days, meaning investor expectations were elevated and the bar for positive surprise was correspondingly high. The combination of barely-in-line guidance and a leveraged acquisition created the conditions for an outsized price correction.
Trending AI Robots
For traders actively monitoring names like FUL during volatile, news-driven sessions, Tickeron's Trending AI Robots page offers a curated selection of its highest-performing AI trading bots under current market conditions. Tickeron runs hundreds of AI-powered bots covering thousands of tickers, spanning a wide range of strategies — from momentum and swing trading to mean reversion — across various timeframes and asset classes. Only bots demonstrating the strongest recent performance metrics make the Trending list, giving traders a data-driven starting point. Each bot is transparent about its traded symbols, historical accuracy, and risk profile. Investors and active traders looking for systematic, AI-assisted approaches to navigating volatile markets may find the Trending AI Robots section a useful resource worth exploring.
What Comes Next for FUL
The most immediate watchpoint for FUL is the evolution of the Ancora situation — whether the activist firm formally escalates toward a proxy contest or seeks board representation in response to the AMS deal confirmation. On the corporate calendar, integration planning details and financing disclosures related to the AMS transaction will be closely watched, particularly how management addresses the projected leverage spike above 4.0x. Credit rating agency commentary could also become a near-term catalyst; any negative rating action tied to the balance sheet expansion may intensify selling pressure. Looking further ahead, FUL's fiscal Q3 earnings — which will be the first report to reflect management's post-deal capital allocation priorities — will be a critical test of whether the company can sustain its margin and cash flow trajectory while absorbing the costs of a large cross-border transaction. Risks include potential delays in the AMS deal closing timeline, continued activist opposition, currency exposure from the sterling-denominated transaction, and the broader macro environment's impact on adhesives demand across construction and industrial end markets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
FUL's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for FUL turned positive on September 25, 2026. Looking at past instances where FUL's MACD turned positive, the stock continued to rise in 29 of 45 cases over the following month. The odds of a continued upward trend are 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FUL's RSI Oscillator exited the oversold zone, 16 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 36 of 58 cases where FUL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
Following a +0.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where FUL advanced for three days, in 156 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FUL as a result. In 55 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FUL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
The Aroon Indicator for FUL entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.226) is normal, around the industry mean (6.363). P/E Ratio (13.752) is within average values for comparable stocks, (209.940). Projected Growth (PEG Ratio) (0.840) is also within normal values, averaging (1.548). Dividend Yield (0.019) settles around the average of (0.013) among similar stocks. P/S Ratio (0.801) is also within normal values, averaging (48.960).
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. FUL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 73 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FUL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is the definition of "undervalued" in the context of value investing?
Revolutionizing Data Processing: AI-Powered Pattern Recognition Systems
Best Oil Fracking Stocks
543% Explosion in CRCL During June & Earnings Insight: AI‑Fueled Rally Sparks Fresh Optimism
Tickeron Launches Space Empire AI Trading Bot: 325% Annualized Return for Retail Investors (RKLB)
General Information
a manufacturer of adhesives, sealants and other chemical products
Industry ChemicalsSpecialty
Advertisement